RIPK2 and inflammatory breast carcinoma: Furthermore, we can observe a positive correlation between active RIPK2 (as monitored by RIPK2 pY474 antibody) and methylation status of RASSF1A in IBC tumor samples [53], to suggest expression loss of RASSF1A with increased levels of RASSF1A CpG methylation, and increased activation of active RIPK2.